(Reuters Health)
The American
College of Physicians (ACP) became the latest group to ask doctors to be
clear about the limited benefits and "substantial harms" of prostate
cancer screening before offering their male patients a prostate-specific
antigen (PSA) test.
The ACP's guidance statement,
published Monday in the Annals of Internal Medicine, also explicitly
recommends against screening men younger than 50, older than 69 or with
less than 10 to 15 years to live.
Men
in their 50s and 60s may weigh the potential benefits and harms of PSA
testing differently, which is why the idea of shared decision-making
between patients and their doctors is so critical, said the ACP's Dr.
Amir Qaseem.
Read the full Reuters Health report
